Pharmacologic: phosphonic acid derivatives
Uncomplicated urinary tract infections in women (acute cystitis).
Inactivates an enzyme crucial for bacterial cell wall synthesis. Decreases adherence of bacteria to uroepithelial cells. Therapeutic Effects: Bactericidal action against susceptible bacteria. Spectrum: Active against Enterococcus faecalis and Escherichia coli.
Adverse Reactions/Side Effects
CNS: dizziness, headache, weakness. GI: PSEUDOMEMBRANOUS COLITIS, diarrhea, dyspepsia, nausea. GU: vaginitis.
PHYSICAL THERAPY IMPLICATIONS
Examination and Evaluation
Be alert for signs of pseudomembranous colitis, including diarrhea, abdominal pain, fever, pus or mucus in stools, or other severe or prolonged GI problems (nausea, cramps, vomiting). Notify physician immediately if these signs occur.
Assess dizziness and weakness that might affect gait, balance, and other functional activities (See Appendix C). Report balance problems and functional limitations to the physician and nursing staff, and caution the patient and family/caregivers to guard against falls and trauma.
Always wash hands thoroughly and disinfect equipment (whirlpools, electrotherapeutic devices, treatment tables, and so forth) to help prevent the spread of infection. Employ universal precautions or isolation procedures as indicated for specific patients.
Instruct patient to report other bothersome side effects such as severe or prolonged headache, vaginal irritation, or GI problems (nausea, diarrhea, indigestion).
Absorption: Rapidly absorbed and converted to fosfomycin, its active component, resulting in 37% bioavailability.
Distribution: Distributes to kidneys and bladder wall; crosses the placenta.
Metabolism and Excretion: Excreted unchanged in urine (38%) and feces (18%).
Contraindicated in: Hypersensitivity; Pyelonephritis; Lactation: Lactation.
Use Cautiously in: OB/Pedi: Pregnancy or children <12 yr (safety not established).
Drug-Drug: Urinary excretion and blood levels are ↓ by metoclopramide.
PO (Adults and Children ≥18 yr): 3 g single dose.